Formulation and Evaluation of Sintered Matrix Tablets of Diltiazem Hydrochloride

 

Preetha S. Panicker1, R. Venkata Krishnan2* and Surekha Repaka3

1Department of Pharmaceutics, Ultra College of Pharmacy, Madurai-20. Tamilnadu                2B-22, Vatsalyam, 7 and 8 Reddy Kuppam Road, Saidapet, Chennai-15, Tamilnadu      3Sri Rama Cloth Shop, Kotturu Junction, Chodavaram, Vishakhapatnam Dist.- 531036, Andhra Pradesh

*Corresponding Author E-mail: rjsv30@gmail.com

 

ABSTRACT:

Diltiazem hydrochloride, a water soluble drug, has a short half life of 3 to 4.5 hours and a limited window of absorption. This necessitates the formulation of this drug as a controlled release tablet. So the present work was aimed to extend the release of diltiazem hydrochloride from matrix tablets by sintering technique. For this purpose polymers like HPMC K4M and HPMC K15M were used. These polymers were added in different concentrations to the active ingredient and other excipients. The formulation was then punched into tablets and kept in a desiccator for 3 hours and 6 hours for sintering. The desiccator must be previously saturated with acetone vapors for 24 hours. After sintering, the tablets were removed from the desiccator, and dried at room temperature for 24 hours to evaporate the adhering acetone and were finally dried in a vacuum desiccator at 30° C over fused calcium chloride for 24 hours to remove the residual acetone from the tablets and stored in desiccator for further studies. The tablets were subjected to all the evaluation tests of tablets. The results proved that tablets sintered for 6 hours were harder and released drug at a slower rate than those sintered for 3 hours. Also HPMC K15M was found to be better rate controlling polymer than HPMC K4M. As a whole, tablets containing HPMC K15M and sintered for 6 hours released drug for longer period of time than the other tablets formulated.

 

KEYWORDS: Diltiazem Hydrochloride, Sintering, HPMC K4M, HPMC K15M.

 


INTRODUCTION:

The most commonly used method of modulating the drug release is to include it in a matrix system. Hydrophilic polymer matrix systems are widely used for designing oral controlled drug delivery dosage forms because of their flexibility to provide a desirable drug release profile, their cost-effectiveness, and broad regulatory acceptance. From a manufacturing standpoint, it is clearly desirable to simply mix the components and compress into tablets.

 

In order to achieve and maintain the concentration of a drug within its effective range, it is often required to take the drug several times a day. But this practice is not without adverse effects. The drug level in the plasma most often fluctuates which may not give the desired effect or an undesirable elevation in its serum level may cause an untoward effect.

 

The concept of controlled release system has begun to play its part in the treatment of illness through the delivery of drugs. The controlled release dosage forms ensure safety and it improves the efficacy of the drugs as well as patient compliance. If the drug has to be fully effective and safe, it should reach the site of action or receptor in the optimum concentration, should remain there for the desired time without spreading itself to other sites and must be rapidly removed from this site when a steady state blood level that is therapeutically effective and non-toxic is achieved 1.

 

Diltiazem, a benzothiazepine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Diltiazem is similar to other peripheral vasodilators 2, 3.

 

Today due to the increased awareness in medical and pharmaceutical community about the importance of safe and effective usage of drugs, development of novel delivery methods and techniques is at the forefront of research and development 1.

 

Modified Release Systems:

The basic rationale of a sustained drug delivery system is to optimize the Biopharmaceutic, Pharmacokinetic and Pharmacodynamic properties of a drug in such a way that its utility is maximized through reduction in side effects and cure or control of condition in the shortest possible time by using smallest quantity of drug, administered by the most suitable route.

 

Oral route has been the most popular and successfully used route for delivery of sustained  release drugs because of convenience and ease of administration, greater flexibility in dosage form design and ease of production and low cost of such a system. The sustained release systems for oral use are mostly solid and based on dissolution, diffusion or a combination of both mechanisms in the control of release of drugs.

 

MATRIX SYSTEMS:

One of the least complicated approaches to the manufacture of sustained release dosage forms involves the direct compression of blends of drug, retardant materials and additives to form a tablet in which drug is embedded in a matrix core of the retardant. Alternately, retardant-drug blends may be granulated prior to compression.

 

The hydrophilic polymers represent non digestible hydrophilic materials that form gel in-situ. Drug release is controlled by penetration of water through a gel layer produced by hydration of polymer and diffusion of drug through the swollen, hydrated matrix, in addition to erosion of the gelled layer. The extent to which diffusion or erosion controls release depends on the polymer selected for the formulation as well as on the drug-polymer ratio.

 

SINTERING: 4

Sintering is defined as the bonding of adjacent particle surfaces in a mass of powder, or in a compact, by the application of heat. Conventional sintering involves the heating of a compact at a temperature below the melting point of the solid constituents in a controlled environment under atmospheric pressure.

The formation of solid bonds within a powder bed during tablet compression was also studied in terms of sintering. The changes in the hardness and disintegration time of tablets stored at elevated temperatures were described as a result of sintering.

 

Theory of sintering:

The principal driving force for sintering is the reduction of total free energy in the system as a result of bonding of particles, void-space shrinkage, and the consequent decrease in total surface area of the compact. Therefore, from the thermodynamic point of view, sintering is a spontaneous process.

 

SINTERING OF PHARMACEUTICAL COMPACTS:

The structural changes within a compact during sintering can be broken down into several stages, some of which may occur virtually simultaneously.

 

Figure 1: Diagram showing different tages in the sintering of Pharmaceutical components

 

Various stages in structural changes occurring within a tablet during sintering:

1.        Inter particle bonding: The transport of molecules at the point of particle contact leads to the formation of physical bonding and grain boundaries. The initial bonding takes place rapidly.

2.        Neck growth: Continuing material transport results in the development of a distinct “neck” between particles. The strength of the compact is considerably enhanced at this stage.

3.        Pore-channel closure: The continuing neck growth leads to the closure of some pore channel within the compact, giving rise to isolated pores.

4.        Pore rounding: As the growth reaches its final stage, the transport of material from the bulk to the neck regions produces a smoothening effect on the pore wall. At this stage, the toughness of the compact is further strengthened.

5.        Pore shrinkage: With further sintering, the pores in the compact start to shrink in size and decrease in numbers. This facilitates further densification. This stage involves extensive material transport and the annihilation of vacancies in the compact.

 

MATERIALS AND METHODS:

Formulation of diltiazem hydrochloride matrix tablets

 

Table 1: Composition of Various Formulations F1 to F6 (wt. of each tablet: 100mg)

Ingredients

F1

(US)

F2

(US)

F3

(S3)

F4

(S6)

F5

(S3)

F6

(S6)

Diltiazem Hydrochloride

60

60

60

60

60

60

HPMC k4m

8

----

8

8

----

----

HPMC k15m

----

8

----

----

8

8

Dicalcium phosphate

19.2

19.2

19.2

19.2

19.2

19.2

Talc

6

6

6

6

6

6

Magnesium stearate

0.8

0.8

0.8

0.8

0.8

0.8

Starch

6

6

6

6

6

6

 (All weights in mg) US: Unsintered; S3: Sintered for 3 hours; S6: Sintered for 6 hours

 

Steps in the manufacture of sintered matrix tablets of Diltiazem hydrochloride:

1.        All the ingredients were added as per the formula (table 1) in geometric dilutions after making sure that all the particles were in a uniform size range.

2.        The formulation was then made into tablets each weighing 100mg by direct compression.

3.        The lower chamber of a desiccator was filled with acetone, closed and kept aside for saturation (24hrs). After saturation the compressed tablets were taken in Petri dishes and placed over a wire-mesh which was kept above the lower chamber of the desiccator containing acetone.

4.        The desiccator was made airtight by closing the lid with the help of wax.

5.        The acetone vapors in the saturated desiccator enter the pores of tablets and solubilize the surface of the polymer particles which results in the fusion of particles, thus bringing about sintering 5.

6.        After sintering, the tablets were removed from the desiccator, and dried at room temperature for 24 hours to evaporate the adhering acetone and were finally dried in a vacuum desiccator at 30° C over fused calcium chloride for 24 hours to remove the residual acetone from the tablets and stored in desiccator for further studies.

 

ANALYTICAL METHODS:

Calibration curve in Phosphate Buffer pH:7.4

100 mg of Diltiazem Hydrochloride was dissolved in phosphate buffer pH 7.4 and the volume was made up to 100 ml in a volumetric flask. From the above stock solution  concentrations of 1,2,3,4,5,6,7,8,9,10 µg/ml were prepared and absorbance was measured at 240nm.

 

COMPATIBILITY STUDIES:

Infrared spectra matching approach was used for the detection of any possible chemical reaction between the drug and the polymer. A physical mixture (1:1) of drug and polymer was prepared and mixed with suitable quantity of potassium bromide and compressed using a hydraulic press at 10 tons pressure to form a transparent pellet. It was scanned from 4000 to 400 cm-1 in a Shimadzu FTIR spectrophotometer. The IR spectrum of the physical mixture was compared with those of pure drug and polymers to detect any appearance or disappearance of peaks 6.

 

POWDER PROPERTIES:

The powders of polymer and drug are characterized by bulk density, tapped density, Carr’s consolidation index and angle of repose. The flow properties of solids have great impact on tableting and encapsulation processes for dosage form manufacturing which require the flow of materials from a storage container to filling stations.

 

Flow Properties of powder:2, 4

Compressibility index (Carr’s consolidation index):

An indirect method of measuring powder flow from bulk density was developed by Carr. The percentage compressibility of a powder is a direct measure of the potential powder arch or bridge strength and stability. It is calculated using the following equation.

 

                                 Tapped density – Bulk density

% Compressibilty= -----------------------------------------x 100

                                              Tapped density

 

Angle of Repose:

A funnel with its bottom closed is fixed to a stand and a weighed quantity of powder is placed in it. The bottom of the funnel is opened and the powder is allowed to fall on a paper and form a pile.  The height of the pile and the diameter of the pile base are used to calculate the angle of repose (the angle made by the slant of the pile with the horizontal surface)8,9.

 

CHARACTERIZATION OF THE TABLET:

The prepared tablets were subjected to various quality control tests to characterize them.

 

Weight Variation:

The weight variation test of the tablets was done as per the guidelines of Indian Pharmacopoeia. Weight of twenty tablets (selected at random) and their individual weights were noted and the mean weight was also calculated. Percentage deviation of each tablet from the mean was calculated.

 

Thickness:

Once the tablet size and shape have been established, tablet thickness remains the only overall dimensional variable. Thickness should be controlled within 5% or less of an established standard value. Excessive variation in tablet thickness can result in problems with packaging as well as consumer acceptance. Variation in tablet thickness can also indicate formulation or processing problems such as change in die fill and compressive force9. The thickness of the individual tablets and average thickness were measured with Vernier calipers.

 

Hardness:

Tablets require a certain amount of mechanical strength to withstand the shock of handling during its manufacturing, packaging, shipping and dispensing. It may be especially important to monitor the tablet hardness for sustained release drug products or other products that posses potential bioavailability problems or are sensitive to variations in drug release profile. The crushing strength that just causes the tablet to break was recorded by means of Monsanto hardness tester.

 

Friability:

Friability is the measure of a tablet’s ability to withstand both shock and abrasion without crumbling during manufacturing, packing, shipping and consumer use. Tablets that tend to powder, chip and fragment when handled lack elegance and hence, consumer acceptance. The weight of 10 tablets was noted and they were then placed in Roche type friabilator. The pre-weighed tablet sample was removed after 100 revolutions, dusted and reweighed. Tablets that loose less than 0.5 to 1 percent in weight are generally considered acceptable 8, 9.

 

Drug content estimation:

From each batch 5 tablets were triturated to form fine powder after knowing the individual weight of each tablet. The powder equivalent to 100mg of Diltiazem hydrochloride was weighed and transferred into a 100 ml volumetric flask and dissolved in phosphate buffer of pH 7.4 and the volume was made up to get 1 mg/ml. 1ml of this stock solution was taken in 100 ml volumetric flask and made up with phosphate buffer of pH 7.4 to get a concentration of 10 μg/ml.  The absorbance of this solution was measured at 240 nm by using UV-Visible spectrophotometer.  The drug content was estimated by using calibration curve.

 

In-vitro Dissolution Studies:

The in-vitro dissolution studies of the tablets were carried out by using USP-dissolution apparatus type-II, using 900 ml of phosphate buffer pH 7.4 as medium maintained at 37 ± 1° C at 100 rpm for 9 hours.

 

Samples of 1ml volume were withdrawn at predetermined time intervals, which were later filtered, suitably diluted and assayed spectrophotometrically at 240 nm. An equal volume of fresh medium was immediately added to maintain the dissolution volume constant. The amount of Diltiazem hydrochloride released at each time interval was calculated from the absorbance of the samples. The percentage drug release was then graphed against time and the release profiles were studied.

 

RESULTS:

Compatibility study:

The compatibility between the drug and the selected polymers (HPMC k4m and HPMC k15m) were evaluated using FTIR peak matching method. There was no appearance or disappearance of peaks in the polymer–drug mixture.

 

Flow properties of powder:

Here angle of repose and compressibility index (CI) were employed to characterize the flow properties of the powder. The results are reported in table no. 2.

 

Table No. 2 Compressibility Index and Angle of Repose of formulations.

S. No.

Formulation

Compressibility Index (%)

Angle of Repose(o)

θ = tan-1 H/R

1.

F1

21.62

16.17

2.

F2

27.16

18.26

F1: Diltiazem HCl+HPMC k4m               ; F2: Diltiazem HCl+HPMC k15m

 

Characterization of the matrix tablets:

Weight variation:

All the batches of tablets complied with the weight variation limits as per Indian Pharmacopoeia10 i.e., the percentage weight variation of the individual tablets remained within 10% and not more than 2 tablets in a batch of 20 deviated from ±10% of the average weight.

Thickness:

Thickness of the tablets was found to remain in the limits of ± 5% of the size.

 

Hardness:

The hardness of the tablets was determined by Monsanto hardness tester and is reported in the table no. 3.

 

 

Table No. 3- Hardness of the manufactured tablets after different sintering times.

Tablet Formulation

Hardness (kg/cm2 )

0 hrs

3 hrs

6 hrs

With HPMC k4m

2.0

2.5

3.0

With HPMC k15m

2.5

3.0

3.5

 

FRIABILITY:

The friability test for all the batches of tablets was carried out and the results are shown in table no. 4.

 

Table No. 4- Friability of Diltiazem Hydrochloride matrix tablets.

Formulation

Percentage friability

F1

0.91

F2

0.10

F3

0.30

F4

0.10

F5

0.20

F6

0.10

 

Drug content estimation:

The manufactured tablets were found to contain not less than 90% and not more than 110% of the labeled amount of Diltiazem hydrochloride 10.

 

In-vitro release studies:

Dissolution test was performed on three tablets from each formulation. The release of diltiazem HCl from different formulations in phosphate buffer of pH 7.4 is reported in table 5.

 

Table No. 5 Data for the in-vitro Release Profile of Diltiazem Hydrochloride from different Formulations.

Time (hrs)

Cumulative % drug release

F1

F2

F3

F4

F5

F6

1

35.00

31.11

30.00

21.00

24.00

18.50

2

62.12

42.20

38.18

27.40

38.12

23.50

3

68.10

54.21

42.10

35.00

42.20

28.80

4

74.01

66.20

54.10

39.10

51.20

36.10

5

78.11

69.10

65.61

46.14

55.10

42.30

6

82.00

75.10

70.10

51.10

60.00

46.10

7

85.10

80.20

75.80

56.40

68.10

54.10

8

87.61

84.00

80.24

60.10

73.22

62.10

9

90.00

86.10

84.10

66.10

75.11

63.21

F1 and F2: Unsintered                              F3 and F5: Sintered for 3hrs          F4 andF6: Sintered for 6hrs

 

Figure 2(a)- In-vitro release profile of unsintered formulations F1 and F2

--------------F1 (Dark Blue line)

--------------F2 (Pink line)

 

Figure 2(b)- In-vitro release profile of sintered formulations F3 to F6

---------- -F3 (Green line)

----------–F5 (Violet line)

----------–F4 (Blue line)

----------–F6 (Red line)

 

 

Figure 2(c)- In-vitro release profile of formulations F1 to F6

(i) --------------F1 (Dark Blue line)

(ii) -------------F2 (Pink line)

(iii) ---------- -F3 (Green line)

(iv) -----------–F5 (Violet line)

(v) ------------–F4 (Blue line)

(vi) -----------–F6 (Red line)

DISCUSSION:

The absence of any remarkable differences in the FTIR spectra of the drug when combined with different polymers confirmed the absence of any chemical interaction between the drug and the polymers.

 

POWDER FLOW PROPERTIES:

It is necessary to characterize the flow properties of powders in order to estimate their suitability for employing them as direct compression excipients. Angle of repose and compressibility index are considered as indirect measurements of powder flow ability. Talc was added to improve the flow characteristics of these mixtures for compression.

 

CHARACTERIZATION OF TABLETS:

Hardness-The comparatively low hardness of the unsintered matrix tablets indicates that the main forces holding the particles together are probably Vander Waals and mechanical forces due to interlocking of the irregularities on the surface of particles. Mild sintering may have occurred due to heat generated during compression, because of the low transition temperature of the polymers.

 

There is a significant difference between the hardness of the un-sintered and sintered matrix tablets which may be attributed to the bridge formation between the polymer particles during sintering that strengthens the tablet. The hardness of the tablets was found to increase with an increase in sintering time.

 

Friability- The exceptionally low friability of the matrix tablets may be attributed to inter-particulate bridges formed during sintering which holds the drug and excipient particles between them very strongly. Some batches that are having higher polymer concentration and subject to longer sintering duration showed no friability which may be because of thicker bridges formed during sintering as the depth to which the polymer particle is solubilized is more and more such bridges are formed due to higher polymer proportion in the matrix.

 

Dissolution test- The unsintered formulations were compared to sintered formulations with respect to dissolution data. The data shows that with constant polymer concentration, the release rate decreased with increasing sintering time.

 

It was evident from table no. 5 that at a particular drug : polymer ratio and sintering time, the release rate and cumulative amount of drug release is more from HPMC K4M matrices than HPMC K15M matrices. This may be due to difference in permeability of water into the polymers.

It is also evident from the Table no. 5 that the release of the drug from the matrix can be controlled by altering the sintering time. From among the sintered formulations F3, F4, F5, F6 the formulation F6 possessing good release retardant ability has fulfilled the objective of our study.

 

CONCLUSIONS:

From the results it can be concluded that

Ø  Among the tablets prepared, sintered formulations exhibited better retardation in the release rate of the drug than the unsintered formulations.

Ø  By employing sintering technology, friability decreased and the hardness of the tablets increased with increasing sintering time. Thus, sintering technique proved to be effective in retarding the release rate of the drug.

Ø  It is also cost effective with a predictable release behavior than the conventional multi-unit pellet preparation method.

Ø  Sintering technique is an alternative technology for the manufacture of sustained release formulations.

 

BIBLIOGRAPHY:

1.        Joseph R. Robinsan, Wincent H Lee. Controlled drug delivery: Fundamentals and applications 2nd edition revised and expanded. Marcel Dekker Inc, New York 1987; iii -iv.

2.        K.D. Tripathi Medical Pharmacology. 6th Edition: Pg 518-534

3.        http://www.drugbank.ca/drugs/DB00343(website)

4.        Encyclopedia of Pharmaceutical Technology. Volume 14; Edited by James Swarbrick and James C. Boylan. Pg 87-101.

5.        Sreenivasa Rao B, Seshasayana A, Himasankar K, Prasanna Raju Y and Ramana Murthy KV. Design and evaluation of ethylene- vinyl acetate sintered matrix tablets. Indian J Pharm Sci.2003; 65(5): Pg 496-502.

6.        Y.S.R Krishanaiah, K. Latha, L. Nageswara Rao. Development of colon targeted oral guar gum matrix tablets of albendazole for the treatment of helminthiasis. Indian J.Pharam. Sci 2003; 65(4): Pg 378 – 384.

7.        Pharmaceutical Dosage Forms Tablets Vol I 2nd Edition by Herbert A Liberman, Leon Lachman; Pg 77 -78.

8.        Alfonso R, Gennaro. Remington: The science and Practice of Pharmacy Vol 1, 20th Edition; Pg 903 – 914.

9.        Leon Lachman, Lieberman H,  Joseph LK, The Theory and Practice of Industrial Pharmacy 3rd edition; Pg 453 – 455

10.     Indian Pharmacopoeia 1996: Pg 256-257

 

 

 

 

 

 

 

Received on 15.10.2010          Modified on 20.11.2010

Accepted on 03.12.2010         © RJPT All right reserved

Research J. Pharm. and Tech. 4(5): May 2011; Page 907-912